Hyrimoz HCF (adalimumab biosimilar) high-concentration formulation is launched in Europe, aiming to improve patient care
Sandoz, announces the launch of Hyrimoz (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe
The medicine will become available to patients progressively across European markets, starting today.
Hyrimoz HCF, like the currently available 50mg/mL version of Hyrimoz, is indicated for all conditions covered by the reference medicine: rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
Rebecca Guntern, President Europe Sandoz said: “People living with chronic inflammatory conditions can experience debilitating effects on daily life. The launch of Hyrimoz HCF in Europe is a key milestone in offering an additional treatment option to those that need it and showcases our unwavering commitment to expanding access to high-quality medicines.”
Hyrimoz citrate-free HCF is an updated formulation (100 mg/mL) to the currently available Hyrimoz 50 mg/mL and offers a 50 percent reduction in injection volume, thereby potentially decreasing the number of injections required for patients who need 80 mg/mL or higher dosing. The HCF formulation is administered with the familiar Hyrimoz SensoReady pen, aiming for an enhanced yet familiar patient experience.